Bayer AG (FRA:BAYN) has been assigned a €125.00 ($147.06) target price by investment analysts at UBS AG in a research report issued to clients and investors on Monday, November 6th, www.boersen-zeitung.de reports. The brokerage currently has a “buy” rating on the healthcare company’s stock. UBS AG’s price target points to a potential upside of 16.01% from the stock’s previous close.
Other equities research analysts have also issued research reports about the company. Deutsche Bank AG set a €124.00 ($145.88) price objective on Bayer and gave the stock a “buy” rating in a report on Monday, July 24th. Commerzbank Ag set a €126.00 ($148.24) price objective on Bayer and gave the stock a “buy” rating in a report on Thursday, July 27th. J P Morgan Chase & Co reissued a “buy” rating and issued a price objective on shares of Bayer in a report on Monday, July 31st. Warburg Research set a €121.00 ($142.35) price objective on Bayer and gave the stock a “buy” rating in a report on Wednesday, September 13th. Finally, Baader Bank set a €120.00 ($141.18) price objective on Bayer and gave the stock a “neutral” rating in a report on Thursday, July 27th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of €122.43 ($144.03).
Shares of Bayer (FRA:BAYN) traded down €0.75 ($0.88) during trading on Monday, hitting €107.75 ($126.76). The stock had a trading volume of 1,522,353 shares. Bayer has a 1 year low of €86.06 ($101.25) and a 1 year high of €123.82 ($145.67).
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with our FREE daily email newsletter.